All Outputs (6)

NOTCH and AKT signalling interact to drive mammary tumour heterogeneity (2023)
Journal Article
Ordonez, L., Tornillo, G., Kendrick, H., Hay, T., & Smalley, M. J. (2023). NOTCH and AKT signalling interact to drive mammary tumour heterogeneity. Cancers, 15(17), Article 4324. https://doi.org/10.3390/cancers15174324

A better understanding of the mechanisms generating tumour heterogeneity will allow better targeting of current therapies, identify potential resistance mechanisms and highlight new approaches for therapy. We have previously shown that in genetically... Read More about NOTCH and AKT signalling interact to drive mammary tumour heterogeneity.

Reproductive history determines ERBB2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model (2021)
Journal Article
Ordonez, L. D., Melchor, L., Greenow, K. R., Kendrick, H., Tornillo, G., Bradford, J., …Smalley, M. J. (2021). Reproductive history determines ERBB2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model. Disease Models and Mechanisms, 14(5), Article dmm048736. https://doi.org/10.1242/DMM.048736

Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments that can target specific tumour subtypes. We have previously targeted CRE recombinase-dependent conditional deletion of the tumour suppressor genes B... Read More about Reproductive history determines ERBB2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours (2019)
Journal Article
Ordonez, L. D., Hay, T., McEwen, R., Polanska, U. M., Hughes, A., Delpuech, O., …Smalley, M. J. (2019). Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours. Oncotarget, 10(27), 2586-2606. https://doi.org/10.18632/oncotarget.26830

Tumours defective in the DNA homologous recombination repair pathway can be effectively treated with poly (ADP-ribose) polymerase (PARP) inhibitors; these have proven effective in clinical trials in patients with BRCA gene function-defective cancers.... Read More about Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.

Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumourigenesis in murine mammary epithelium (2016)
Journal Article
Reed, K., Daly, C., Shaw, P., Ordonez, L., Williams, G., Quist, J., …Clarke, A. (2016). Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumourigenesis in murine mammary epithelium. European Journal of Cancer, 61(S1), S52-S53. https://doi.org/10.1016/s0959-8049%2816%2961177-2

Aberrant Wnt signaling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast tissue remains poorly understood and the consequences of immediate or long-term dysregulation remain elusive. The exact contributi... Read More about Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumourigenesis in murine mammary epithelium.

Mouse mammary stem cells express prognostic markers for triple-negative breast cancer (2015)
Journal Article
Soady, K. J., Kendrick, H., Gao, Q., Tutt, A., Zvelebil, M., Ordonez, L. D., …Smalley, M. J. (2015). Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Research, 17(1), Article 31. https://doi.org/10.1186/s13058-015-0539-6

Introduction: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours in which chemotherapy, the current mainstay of systemic treatment, is often initially beneficial but with a high risk of relapse and metastasis. There is currently... Read More about Mouse mammary stem cells express prognostic markers for triple-negative breast cancer.

What are the best routes to effectively model human colorectal cancer? (2013)
Journal Article
Young, M., Ordonez, L., & Clarke, A. R. (2013). What are the best routes to effectively model human colorectal cancer?. Molecular Oncology, 7(2), 178-189. https://doi.org/10.1016/j.molonc.2013.02.006

Colorectal cancer (CRC) is the third most common cancer in the UK, with over 37,500 people being diagnosed every year. Survival rates for CRC have doubled in the last 30 years and it is now curable if diagnosed early, but still over half of all suffe... Read More about What are the best routes to effectively model human colorectal cancer?.